Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Jan
4
2024
Espresso Yourself: When Prosecution History as a Whole Doesn’t Demonstrate Clear, Unmistakable Disclaimer McDermott Will & Emery
Jan
4
2024
Same Applicant, Similar Claims Support Obviousness-Type Double Patenting Rejection McDermott Will & Emery
Jan
3
2024
NIOSH Reviews Past Nanotechnology Guidance and Needs for Future Research Bergeson & Campbell, P.C.
Jan
3
2024
DOT Random Drug and Alcohol Testing Rates for 2024 Jackson Lewis P.C.
Jan
3
2024
Defending Psychedelics: Congress Includes Psychedelic Provisions in Defense Authorization Act Bradley Arant Boult Cummings LLP
Jan
3
2024
Federal Circuit Clarifies Reach of “Artificial” Act of Patent Infringement Proskauer Rose LLP
Jan
3
2024
Unpacking Averages: The Seasonality of FDA 510(k) Decision-Making and the Impact of Michigan Playing for a National Championship Epstein Becker & Green, P.C.
Jan
3
2024
FDA Supplements Response to D-Tagatose Petition Keller and Heckman LLP
Jan
3
2024
FDA Issues Guidance on Reformulating Drug Products that Contain Carbomers Manufactured with Benzene Keller and Heckman LLP
Jan
3
2024
APHIS Reopens Comment Period on Proposed Additional Exemptions for Plants Modified or Produced Through Genetic Engineering Bergeson & Campbell, P.C.
Jan
2
2024
New U.S. Action Against Wine Bottle Imports Squire Patton Boggs (US) LLP
Jan
2
2024
US State Law Roundup – 2023 Year-end Update Squire Patton Boggs (US) LLP
Jan
2
2024
The Intertwining Nature of Motivation to Combine and Reasonable Expectation of Success Sheppard, Mullin, Richter & Hampton LLP
Jan
2
2024
Looking Back and Moving Forward: MoCRA Regulatory Developments Ring in the New Year Mintz
Jan
2
2024
Prop 12 Takes Full Effect in California Keller and Heckman LLP
Dec
29
2023
OSTP Publishes Report on Vision, Needs, and Proposed Actions for Data for the Bioeconomy Initiative Bergeson & Campbell, P.C.
Dec
29
2023
EPA Registers Novel Pesticide Technology for Potato Crops Bergeson & Campbell, P.C.
Dec
28
2023
Two-Dimensional Barcodes: How 2D Could Change Retail Foley & Lardner LLP
Dec
27
2023
NNI Publishes Economic Impact Analysis of 20 Years of Nanotechnology Investments Bergeson & Campbell, P.C.
Dec
27
2023
Postal ServiceTM Proposes New Mailing Standards for Hazardous Materials Outer Packaging and Nonregulated Toxic Materials Bergeson & Campbell, P.C.
Dec
26
2023
CMS Issues Revised Guidance Implementing Medicare Inflation Rebates Under the Inflation Reduction Act ArentFox Schiff LLP
Dec
23
2023
China’s National Intellectual Property Administration to Allow Third-Party Challenges to Pharmaceutical Patent Term Extensions Schwegman, Lundberg & Woessner, P.A.
Dec
22
2023
Private Investors and Digital Health Attracting OIG Attention: General Compliance Program Guidance to Watch McDermott Will & Emery
Dec
22
2023
Medicare Provider and Supplier Enrollment Requirements: Program Integrity Changes for 2024 McDermott Will & Emery
Dec
21
2023
China’s State Council Releases Amended Implementing Regulations of the Patent Law Schwegman, Lundberg & Woessner, P.A.
Dec
21
2023
Pharmaceutical Companies Have Rights if the Federal Government Seized their Patents Sheppard, Mullin, Richter & Hampton LLP
Dec
21
2023
Inherent Limitations in Prior Patents can Lead to Obviousness-Type Double-Patenting Mintz
Dec
21
2023
FDA Announces Updated Instructions for Serious Adverse Event Reporting for Cosmetic Products ArentFox Schiff LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins